LOS ANGELES, Jan. 13, 2015 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to the market, is excited to officially announce its new website viadermalicensing.com. The new site features extensive company information that has been carefully revamped in preparation for increased marketing, sales and distribution efforts which will be a focus in 2015.
"We are excited to have a new website and company materials that are more closely aligned with our company mission," says ViaDerma CEO Dr. Christopher Otiko. "Our company has reached a turning point in its growth process where we are now ready to share our story with the public."
The new ViaDerma website offers easy-to-navigate functionality and is content-rich, showcasing technology, special characteristics, usage and application, and honors and awards of the lead product, TetraStem. Visitors will have the capabilities to learn more about ViaDerma's innovative technology, see real case study results and stay up to date on company news on the new viadermalicensing.com.
ViaDerma is excited to continue exploring new marketing opportunities and grow the brand in 2015. The company's website has been set in preparation of the forecasted increase of traffic to come this year.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
Forward Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. Christopher Otiko
Chief Executive Officer
ViaDerma, Inc.
info@viadermalicensing.com
818-836-2475
